{"id":"W4311746946","doi":"10.1093/ofid/ofac492.109","title":"1586. Phase 3/3b Experience with Long-Acting Cabotegravir and Rilpivirine: Efficacy and Safety Outcomes Through Week 96 by Race","year":2022,"lang":"en","type":"article","venue":"Open Forum Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"Regeneron Pharmaceuticals; Gilead Sciences; Moderna; Pfizer; Eli Lilly and Company","keywords":"Rilpivirine; Medicine; Regimen; Human immunodeficiency virus (HIV); Internal medicine; Viral load; Antiretroviral therapy; Virology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00009003598,0.0003233863,0.000501933,0.0000627164,0.001015515,0.0001655718,0.0001287054,0.00003038284,0.0004010377],"category_scores_gemma":[0.00006557371,0.0002463006,0.00005267022,0.0002551875,0.0001565708,0.0004366732,0.000442298,0.0001735305,0.000009532637],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001542524,"about_ca_system_score_gemma":0.0001739122,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003692523,"about_ca_topic_score_gemma":0.0001035475,"domain_scores_codex":[0.9984,0.00007428408,0.0002699101,0.0005398552,0.0003185284,0.0003974594],"domain_scores_gemma":[0.9991195,0.000170558,0.0001054509,0.0002973301,0.00003786971,0.0002692969],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.00123206,0.002291524,0.9758486,0.00003928326,0.0003402953,0.0002356282,0.001978195,0.000008107423,0.00006097973,0.0001977142,0.003664977,0.01410259],"study_design_scores_gemma":[0.104268,0.007507345,0.57245,0.0004119084,0.002092097,0.001445671,0.01946996,0.0001547143,0.001895016,0.000304455,0.287552,0.002448818],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.989131,0.001207497,0.0001602551,0.002582774,0.00009019762,0.00152395,0.000142772,0.000121894,0.005039644],"genre_scores_gemma":[0.9904437,0.0002065817,0.0001744703,0.0007133529,0.00001524126,0.0003472088,0.0002135292,0.00004428461,0.007841619],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4033987,"threshold_uncertainty_score":0.9999989,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0135506882634918,"score_gpt":0.3114046751923415,"score_spread":0.2978539869288497,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}